Clinical Trial Search

Phase 3 N=164 Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation

Chronic Idiopathic Constipation

Primary: Number of Spontaneous Bowel Movements (SBMs) Within 1 Week — 4.6; 4.0 number of SBMs — p=0.1290

Mallinckrodt Results Dec 2019 0.0% serious AE View details

Phase 3 N=580 A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis

Scleroderma, Systemic

Primary: Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks — -93.3; -52.4 millilitre (mL)/year (yr) — p=0.0350

Boehringer Ingelheim Results Dec 2019 29.0% serious AE View details

Phase 3 N=25 Oral Versus Topical Antibiotics for Chronic Rhinosinusitis Exacerbations

Chronic Rhinosinusitis

Primary: Change in Rhinosinusitis Disability Index (RSDI) Score — -8.000; -14.82 units on a scale — p=0.505

University of Rochester Results Dec 2019 0.0% serious AE View details

Phase 3 N=543 A phase3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects With Subclinical Atherosclerosis

Atherosclerosis

Primary: Annualized Rate of Change in Mean of the Maximum (MeanMax) CIMT Measurements From Each of the 12 Carotid Artery Sites Based on All Scans Performed During the 104-Week…

AstraZeneca Results Dec 2019 13.3% serious AE View details

Phase 3 N=621 A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting

HER2+ Metastatic Breast Cancer (MBC)

Primary: Centrally Assessed Progression Free Survival — 8.8; 6.6 months — p=0.0059

Puma Biotechnology, Inc. Results Dec 2019 31.9% serious AE View details

Phase 3 N=127 A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis

Moderate to Severe Psoriasis · Generalized Pustular Psoriasis and Erythrodermic Psoriasis

Primary: Percentage of Subjects Achieving a 75 % or Higher Improvement in Psoriasis Area and Severity Index (PASI) Score at Week 16 — 7.9; 73.0; 87.1 percentage of participants…

UCB Biopharma S.P.R.L. Results Dec 2019 5.1% serious AE View details

Phase 3 N=380 Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients

Hepatitis C, Chronic

Primary: Undetectable HCV RNA (ITT Population) — 121; 233 Participants — p=<0.05

Kirby Institute Results Dec 2019 0.8% serious AE View details

Phase 3 N=387 Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

Dermatitis, Atopic

Primary: Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to 2 Points Improvement…

Pfizer Results Dec 2019 3.4% serious AE View details

Phase 3 N=206 A Safety And Immunogenicity Study Of A 13-valent Pneumococcal Conjugate Vaccine In Japanese Subjects Aged 6 To 64 Years.

Pneumococcal Infections

Primary: Percentage of Participants Reporting Pre-Specified Local Reactions Within 7 Days After Vaccination in Participants Aged Between 6 to <18 Years — 21.3; 10.6; 10.6; 0.0…

Pfizer Results Dec 2019 0.0% serious AE View details

Phase 3 N=60 Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK)

Primary Open Angle Glaucoma · Ocular Hypertension

Primary: Intraocular Pressure (IOP) — 13.60; 12.13; 13.19; 11.80 mmHg — p=0.013

Laboratorios Sophia S.A de C.V. Results Dec 2019 0.8% serious AE View details

Phase 3 N=50 Melatonin Effect in Combination With Neoadjuvant Chemotherapy to Clinical Response in Locally Advanced Oral Squamous Cell Carcinoma

Oral Squamous Cell Carcinoma · Neoadjuvant Chemotherapy

Primary: Clinical Response as Measured by RECIST 1.1. Criteria — 5; 5; 8; 7 Participants

Indonesia University Results Dec 2019 0.0% serious AE View details

Phase 3 N=79 Prevention of Obesity in Women Via Estradiol Regulation

Obesity

Primary: Resting Energy Expenditure (REE) — -37.8; -87.2; 14.6; -19.3 kcal/d — p=<0.05

University of Colorado, Denver Results Dec 2019 1.4% serious AE View details

Phase 3 N=157 Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease

Crohn's Disease

Primary: Induction Phase: Percentage of Participants With Crohn's Disease Activity Index (CDAI)-100 Response — 26.6; 16.7 percentage of participants — p=0.1448

Takeda Results Dec 2019 28.9% serious AE View details

Phase 3 N=307 Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients

Plasma Cell Myeloma

Primary: Progression Free Survival (PFS) — 6.47; 11.53 months — p=0.0005

Sanofi Results Dec 2019 67.4% serious AE View details

Phase 3 N=440 A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000®

18-42 Year Old Healthy Vaccinia-naïve Subjects

Primary: Plaque Reduction Neutralization Test (PRNT) Geometric Mean Titer (GMT) at the Peak Visits — 153.5; 79.3 Titer

Bavarian Nordic Results Dec 2019 1.0% serious AE View details